Annexin Pharmaceuticals AB today announces favourable findings in the company's ongoing Proof of Concept Phase 2a study with the drug candidate ANXV in Diabetic Retinopathy (DR) and Retinal Vein Occlu ...
Is the Galleri multi-cancer blood test worth it? A doctor's analyses of real-world performance data. Learn why no major ...
There are a lot of questions, and differing answers, about Century II and a new performing arts center as they relate to the ...
Informed by AI, ideas to supercharge meetings at every level, from board governance & strategy to task-oriented; from ...
Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company.
The power of artificial intelligence (AI) and advanced computing has made it possible to design genetic sequences encoding ...
As work hours and incomes have picked up after Covid, the stresses of working for yourself or running your own business could be getting easier to handle.
In an industry where publications affect promotions and grant acceptances, this delay is significant, said the study, ...
Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ...
Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...
Emerging data show that many patients with drug-resistant epilepsy may be slipping through the cracks of standard clinical ...
A California woman is accusing major social media companies of designing their products to be addictive, especially to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results